Where Does Verona Pharma PLC - ADR (VRNA) Stock Fall in the Biotechnology Field After It Is Lower By -18.10% This Week?

Verona Pharma PLC - ADR (VRNA) is near the top in its industry group according to InvestorsObserver. VRNA gets an overall rating of 89. That means it scores higher than 89 percent of stocks. Verona Pharma PLC - ADR gets a 98 rank in the Biotechnology industry. Biotechnology is number 26 out of 148 industries.

VRNA has an Overall Score of 89. Find out what this means to you and get the rest of the rankings on VRNA!

See Full VRNA Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 89 means the stock is more attractive than 89 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Verona Pharma PLC - ADR Stock Today?

Verona Pharma PLC - ADR (VRNA) stock is lower by -2.42% while the S&P 500 has risen 0.77% as of 3:14 PM on Thursday, Aug 25. VRNA is down -$0.26 from the previous closing price of $10.76 on volume of 276,786 shares. Over the past year the S&P 500 has fallen -7.20% while VRNA has risen 70.45%. VRNA lost -$0.92 per share the over the last 12 months. Click Here to get the full Stock Report for Verona Pharma PLC - ADR stock.